---

Clinical Report: Beyond Bone Density: How Fracture Risk Is Changing Osteoporosis Management

Overview

Osteoporosis management is evolving to emphasize fracture risk assessment alongside bone mineral density. Clinicians are tailoring treatment strategies based on individual fracture history and risk assessment, particularly for patients with prior fragility fractures.

Background

Osteoporosis is a significant health concern, particularly in older populations, where fractures can lead to severe morbidity and increased mortality. Traditional management has focused on bone mineral density, but recent evidence suggests that fracture risk assessment is crucial for treatment planning.

Data Highlights

Recent studies indicate that patients with a history of fragility fractures are at a substantially higher risk for future fractures. Additionally, fracture risk assessment tools, such as FRAX, have been validated to aid in identifying individuals at high risk for fractures, thus guiding treatment decisions.

Key Findings

• Fracture history is a critical predictor of future fracture risk.

• Patients with a prior fragility fracture are at increased risk for subsequent fractures.

• Current guidelines recommend screening for osteoporosis based on individual risk factors.

• Bone-building therapies may be beneficial for patients at very high fracture risk.

• Infusion therapies are an option for patients unable to tolerate oral medications.

Clinical Implications

Clinicians should assess fracture risk in addition to bone density when determining treatment strategies for osteoporosis.

Conclusion

The evolving landscape of osteoporosis management emphasizes the importance of fracture risk assessment.

Related Resources & Content

1. Archives of Orthopaedic and Trauma Surgery, 2026 -- Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study

2. Baptist Health South Florida -- Rethinking Distal Radius Fractures: Evolving Strategies for the Active Osteoporotic Patient

3. Frontiers in Endocrinology -- Editorial: Metabolic and biomechanical factors in bone fragility: new frontiers in understanding and managing osteoporosis

4. Risk Factors Associated with Subsequent Fragile Hip Fractures in a Cohort of 1130 Patients Treated at Oulu University Hospital from 2013 to 2016: A Retrospective Analysis

5. Recommendation: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce

6. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis - PMC

7. Advances in the management of osteoporosis

8. Revised Swedish FRAX models and the establishment of age-dependent intervention thresholds | Osteoporosis International | Springer Nature Link

9. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024 - PMC

10. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis | New England Journal of Medicine

11. Romosozumab Treatment in Postmenopausal Women with Osteoporosis | New England Journal of Medicine

12. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial - PMC

13. A systematic review and meta-analysis of sequential treatment strategies for osteoporosis - PubMed

14. Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis - PubMed

15. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024 - PMC

16. Denosumab discontinuation and fracture risk: getting the balance right - Kim - Internal Medicine Journal - Wiley Online Library

---